TrialJournal of Crohn's & colitis2017

Pharmacokinetics and Exposure-response Relationship of Golimumab in Patients with Moderately-to-Severely Active Ulcerative Colitis: Results from Phase 2/3 PURSUIT Induction and Maintenance Studies.

Omoniyi J Adedokun et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.